The Valens Company Awarded Wholesale Licences to Sell and Supply Cannabis-Derived Medical Products in Australia

KELOWNA, BC, Nov. 3, 2020 /CNW/ –The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF) (the “Company” or “The Valens Company”),a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products, today announced that the Victoria State Government in Australia has granted its wholly-owned subsidiary, Valens Australia Pty Ltd. (“Valens Australia”), the wholesale licences required to sell and supply Schedule 4 andContinue reading “The Valens Company Awarded Wholesale Licences to Sell and Supply Cannabis-Derived Medical Products in Australia”

The Valens Company Manufactures Record Number of Product SKUs in the Third Quarter of Fiscal 2020

– The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF) (the “Company” or “The Valens Company”),a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products, today announced that 56 white label and custom manufacturing product SKUs were produced in the third quarter of 2020, a 56% increase from 36 SKUs in the second quarter of 2020.Continue reading “The Valens Company Manufactures Record Number of Product SKUs in the Third Quarter of Fiscal 2020”

Zenabis Provides Corporate Update

VANCOUVER, BC, Sept. 15, 2020 /CNW/ – Zenabis Global Inc. (TSX: ZENA) (“Zenabis” or the “Company“) today provided its monthly operational update for August, 2020.   Highlights Shai Altman assumed the role of Zenabis’ Chief Executive Officer on September 1, 2020. The Company shipped approximately 4,700 kg of cannabis in the first two months of the third quarter of 2020,Continue reading “Zenabis Provides Corporate Update”

Zenabis Announces First Shipment to Australia

Cannabis Shipment Volume Over First Two Months of Third Quarter ~20% Higher Than Cannabis Shipment Volume Over Entire Second Quarter – Zenabis Global Inc. (TSX: ZENA) (“Zenabis” or the “Company“) today announced that its first shipments to Australia from its Zenabis Atholville facility was completed on August 28, 2020. Zenabis has commenced the supply of packaged cannabis flower under aContinue reading “Zenabis Announces First Shipment to Australia”

VIVO Cannabis™ Announces Second Quarter 2020 Results

Net revenue of $9.4 million – an increase of 15% over Q1 2020 and 79% over Q2 2019 Achieved 68% Ontario retail market share in the concentrates category, including first-to-market shatter by Fireside™ X Entered product supply and clinical services agreements with Medical Cannabis by Shoppers™ Canna Farms™ is the fourth most recognized cannabis brand, according to recent BrightfieldContinue reading “VIVO Cannabis™ Announces Second Quarter 2020 Results”

MediPharm Labs to Participate at CBD BioPharma Virtual Investor Conference

 — MediPharm Labs Corp., (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that MediPharm Labs’ management will participate in the CBD BioPharma Virtual Investor Conference on Thursday, July 9th.  The audio webcast presentation will begin atContinue reading “MediPharm Labs to Participate at CBD BioPharma Virtual Investor Conference”

The Valens Company Enters Australia’s Rapidly Expanding Cannabis Market with Five Year Distribution Agreement with Country’s Largest Distributor

Landmark agreement provides The Valens Company with strategic access to the second largest cannabis market outside of North America. Under the terms of the five-year agreement, The Valens Company becomes a preferred supplier to Cannvalate, a leading authority in the Australian medical cannabis community with the largest cannabis distribution platform in the country. Partnership provides theContinue reading “The Valens Company Enters Australia’s Rapidly Expanding Cannabis Market with Five Year Distribution Agreement with Country’s Largest Distributor”